GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xlife Sciences AG (XSWX:XLS) » Definitions » EBIT

Xlife Sciences AG (XSWX:XLS) EBIT : CHF4.92 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Xlife Sciences AG EBIT?

Xlife Sciences AG's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was CHF15.61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF4.92 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Xlife Sciences AG's annualized ROC % for the quarter that ended in Dec. 2023 was -4.36%. Xlife Sciences AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 1,208.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Xlife Sciences AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.04%.

Xlife Sciences AG EBIT Historical Data

The historical data trend for Xlife Sciences AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xlife Sciences AG EBIT Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 1.60 21.38 53.69 4.73 4.92

Xlife Sciences AG Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.80 -12.00 16.73 -10.69 15.61

Competitive Comparison of Xlife Sciences AG's EBIT

For the Biotechnology subindustry, Xlife Sciences AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xlife Sciences AG's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's EV-to-EBIT falls into.


Xlife Sciences AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF4.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG  (XSWX:XLS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Xlife Sciences AG's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-18.69 * ( 1 - -15.28% )/( (477.551 + 510.803)/ 2 )
=-21.545832/494.177
=-4.36 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=477.941 - 0.715 - ( 0.512 - max(0, 1.917 - 1.592+0.512))
=477.551

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=511.994 - 0.972 - ( 0.219 - max(0, 5.832 - 18.118+0.219))
=510.803

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Xlife Sciences AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=31.22/( ( (0.523 + max(-1.045, 0)) + (0.394 + max(4.251, 0)) )/ 2 )
=31.22/( ( 0.523 + 4.645 )/ 2 )
=31.22/2.584
=1,208.20 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.749 + 0 + 0.014) - (0.715 + 0 + 1.093)
=-1.045

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.127 + 0 + 0.004999999999999) - (0.972 + 0 + 3.909)
=4.251

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Xlife Sciences AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=4.918/241.661
=2.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG EBIT Related Terms

Thank you for viewing the detailed overview of Xlife Sciences AG's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Xlife Sciences AG (XSWX:XLS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xlife Sciences AG (XSWX:XLS) » Definitions » EBIT
Comparable Companies
XSWX:IDIA XSWX:SANN XSWX:MOLN XSWX:NWRN XSWX:RLF XSWX:EVE XSWX:SPEX XSWX:BSLN XSWX:OBSN XSWX:ADXN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
XLSz:UK
Address
Talacker 35, Zürich, CHE, 8001
Website
https://www.xlifesciences.ch
Xlife Sciences AG is a Swiss company with a focus on performance technologies in life sciences. The company allows its investors a very early and direct Entry into the further development of innovative and future-oriented technologies.

Xlife Sciences AG (XSWX:XLS) Headlines

No Headlines